Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors

BACKGROUND: Octreotide has been used for decades in the United States (US) and Europe to treat patients with advanced neuroendocrine tumors (NETs). Lanreotide was approved in 2014 to improve progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally ad...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Gastrointest Oncol
Hoofdauteurs: Saif, Muhammad Wasif, Parikh, Rohan, Ray, David, Kaye, James A., Kurosky, Samantha K., Thomas, Katharine, Ramirez, Robert A., Halfdanarson, Thorvardur R., Beveridge, Thomas J. R., Mirakhur, Beloo, Nagar, Saurabh P., Soares, Heloisa P.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: AME Publishing Company 2019
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6657323/
https://ncbi.nlm.nih.gov/pubmed/31392048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.03.11
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items